Hologic, Inc. HOLX recently announced the commercial availability of its Genius AI Detection technology post its FDA approval. Notably, the latest technology is a deep-learning-based software which has been designed to aid radiologists to detect subtle potential cancers in breast tomosynthesis (an imaging or X-ray technique used to screen for early signs of breast cancer in women with no symptoms) images.
For investors’ note, the Genius AI Detection software is the only 3D computer-aided detection (“CAD”) solution that supports Hologic’s other tomosynthesis imaging technology (Clarity HD and 3DQuorum imaging) along with standard-resolution tomosynthesis.
With the latest commercial availability, Hologic aims to strengthen its foothold in the global Mammography Solutions business. Notably, Mammography Solutions is a segment of its broader Breast Health arm.
Significance of the Approval
The latest technology is an important step toward the early detection of breast cancer. Studies have demonstrated that the Genius AI Detection software aids